FDA Approves Halaven (eribulin mesylate) for the Treatment of Liposarcoma

January 28, 2016 -- The U.S. Food and Drug Administration today approved Halaven (eribulin mesylate), a type of chemotherapy, for the treatment of liposarcoma (a specific type of soft tissue sarcoma) that cannot be removed by surgery (unresectable)...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news